10.14.25 -- Paying For Lots Of Formulation Work At Your CDMO

Join Applied StemCell's webinar with Ruby Tsai, Ph.D., to explore how developers are tackling durability challenges in allogeneic cell therapies. Gain insights into approved therapies, treatments in clinical trials, and novel approaches still in development. Learn how genome engineering and iPSC technologies are enabling scalable, cost-effective solutions that could transform accessibility and impact in the future of cell-based therapies. Click here to learn more.

Understanding these synergies and their impact on efficiency, safety, and cost-effectiveness is essential for stakeholders navigating the complexities of cell and gene therapy development and production.

To ensure the success of gene therapy, learn why it is crucial to partner with a contract research organization that can navigate the challenges of viral vector development and testing.

This session is designed for teams developing new products, optimizing processes, or preparing regulatory submissions, and provides practical tools for a better approach to E&L management.

Daily communication and periodic project- and individual team-level meetings are important. But according to one outsourcing professional with decades of experience, do not overlook the importance of biannual (or quarterly) meetings to ensure outsourcing success.

Learn about the Windsor Framework and how it addresses the challenges of medicine supply chains between the UK and the EU, creating stability and certainty in the post-Brexit world.

Standardized methods, materials, and analytics are critical for overcoming hurdles in the gene therapy space. Explore how a platform approach to fast-track AAVs can enhance quality and efficiency.

Accelerate mRNA drug development by leveraging pre-optimized ionizable lipids and reagent kits that streamline early-stage hurdles and speed candidates to the clinic.

Follow along as President and Chief Scientific Officer, Ruby Tsai, Ph.D., explores innovative strategies for developing hypoimmunogenic cells, a critical advancement for the field of allogeneic cell therapies. 

Here, we highlight real-world applications of AI in gene therapy, providing case studies and addressing the challenges and prerequisites for successful implementation.

With hundreds of members spanning over 25 countries, ARM serves as a hub for innovation, policy development, and cross-sector collaboration in regenerative medicine.

An integrated approach to mRNA drug product manufacturing helps to accelerate drug development, mitigate risks, and ultimately deliver life-changing therapies to patients.

If you don’t know where you are going, how will you get there? Articulating the destination of your therapeutic is essential for determining whether it is commercially viable and meets required milestones.

This Touchlight and ElevateBio webinar explores how non-viral methods are transforming T cell engineering by overcoming cost, safety, and scalability challenges of viral transduction. Speakers highlight CRISPR-based editing with mbDNA™ paired with Life Edit’s LEG14 nuclease. Data show mbDNA™ enabled efficient, precise TCR knock-in with superior performance over Plasmid (next generation circular double stranded) offering a scalable path to next-generation T cell therapies. Click here to learn more.

Consider the benefits of a new cryogenic storage tank and how this innovative technology will mitigate risk in the cell and gene therapy supply chain.

By fostering strong collaborations and maintaining flexibility, BaseCamp is preparing for the complex landscape of commercial manufacturing while prioritizing quality, efficiency, and patient access.

Cell therapies hold immense promise, but navigating the development process can be daunting. A strategic partner can bridge the gap between early-stage innovation and successful commercialization.

As an experienced global CDMO, we're dedicated to meeting your evolving virotherapy development and manufacturing needs through a collaborative approach.

Advance your biologics from preclinical to commercial stages with a flexible CMC platform backed by global development labs and scalable GMP manufacturing capacity.

Focusing on critical parameters such as cell culture conditions, viral vector yield, and downstream purification strategies, can drive the success of scale-up and scale-down models for AAV production.